Ibrutinib Therapy for Lymphoplasmacytic Lymphoma

American Journal of Hematology - United States
doi 10.1002/ajh.24795
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation

Mediterranean Journal of Hematology and Infectious Diseases
Infectious DiseasesHematology
2019English

Incidental Lymphoplasmacytic Lymphoma Diagnosed Following Robotic Assisted Laparoscopic Prostatectomy for Prostate Cancer

European Urology, Supplements
Urology
2018English

IgA-producing Lymphoplasmacytic Lymphoma Carrying the Chromosomal Abnormality T(8;14)

Journal of clinical and experimental hematopathology : JCEH
Medicine
2019English

Plasma Cell Leukemia Masquerading as Lymphoplasmacytic Lymphoma: A Diagnostic Challenge

Journal of Hematopathology
Forensic MedicinePathologyHematologyHistology
2019English

Novel Chemotherapy-Free Combination Regimen for Ibrutinib-Resistant Mantle Cell Lymphoma

British Journal of Haematology
Hematology
2017English

Ibrutinib Plus Palbociclib Has Efficacy in Mantle Cell Lymphoma

Cancer Discovery
Oncology
2019English

BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma

Community Oncology
2013English

Familial Aggregation of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia With Solid Tumors and Myeloid Malignancies

Acta Haematologica
MedicineHematology
2012English

Ibrutinib as Initial Therapy for Elderly Patients With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma: An Open-Label, Multicentre, Phase 1b/2 Trial

The Lancet Oncology
Oncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy